(Q37510912)

20 August 2017

1 reference

title

Abetimus sodium: a medication for the prevention of lupus nephritis flares (English)

1 reference

20 August 2017

1 reference

Diane M Horowitz

1

1 reference

20 August 2017

Richard A Furie

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

9

1 reference

20 August 2017

page(s)

1501-1507

1 reference

How did cyclophosphamide become the drug of choice for lupus nephritis?

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Immunological studies concerning the nephritis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Pharmacological intervention in antibody mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Workshop report on some new ideas about the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560902946419

10.1517/14656560902946419

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference